EY

Report: Biopharmaceutical M&A expected to soar in 2017

Monday, January 16, 2017

The biopharmaceutical industry’s desire for inorganic growth is expected to intensify an already heated mergers and acquisitions (M&A) environment in 2017. This is according to the EY M&A Outlook and Firepower Report 2017. With new regulatory and tax environments expected following the changing geopolitical landscape, most notably in the post-election U.S., expectations are that the industry may roar past the $200 billion in global M&A deal volume seen in the last three years.

[Read More]